Write in a clean editor, then format for Current Controlled Trials in Cardiovascular Medicine in one click — DocuGuru applies the official BMC (BioMed Central) template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Current Controlled Trials in Cardiovascular Medicine is a peer-reviewed journal published by BMC (BioMed Central), covering Blood Pressure and Hypertension Studies, Health Systems, Economic Evaluations, Quality of Life, Lipoproteins and Cardiovascular Health.
| Publisher | BMC (BioMed Central) |
|---|---|
| Reference style | Numbered (Vancouver) Numbered — [1], [2] in the text 1. Smith A, Jones B, Lee C. A representative article title. Current Controlled Trials in Cardiovascular Medicine. 2023;12(3):45–58.
Formats any DOI in Current Controlled Trials in Cardiovascular Medicine style. No sign-up. |
| Publishes research in | Blood Pressure and Hypertension Studies Health Systems, Economic Evaluations, Quality of Life Lipoproteins and Cardiovascular Health Coronary Interventions and Diagnostics Heart Failure Treatment and Management |
| ISSN | 1468-6694 |
| h-index | 23 |
| i10-index | 35 |
| Total citations | 1,721 |
| Article processing charge | $1,680 |
| Open access | Yes |
| Top institutions publishing here | Wake Forest University |
| Journal website | link.springer.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
BACKGROUND: Surrogate measures for cardiovascular disease events have the potential to increase greatly the efficiency of clinical trials. A leading candidate for such a surrogate is the progression of intima-media thickness (IMT) of the carotid artery; much experience has been gained with this endpoint in trials of HMG-CoA reductase inhibitors (statins). METHODS AND RESULTS: We…
Acommon problem in clinical trials is the missing data that occurs when patients do not complete the study and drop out without further measurements. Missing data cause the usual statistical analysis of complete or all available data to be subject to bias. There are no universally applicable methods for handling missing data. We recommend the…
Previous trials (Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure [MERIT-HF], Cardiac Insufficiency Bisoprolol Study [CIBIS] II) have demonstrated a mortality benefit of beta-adrenergic blockade in patients with mild to moderate heart failure. The recent Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial has extended these results to a more advanced patient population. This trial…
BACKGROUND: The high incidence of cardiovascular disease in patients with end stage renal disease (ESRD) is related to the accumulation of uremic toxins in the middle and large-middle molecular weight range. As online hemodiafiltration (HDF) removes these molecules more effectively than standard hemodialysis (HD), it has been suggested that online HDF improves survival and cardiovascular…
BACKGROUND: Patients with end-stage renal disease (ESRD) are at high risk of cardiovascular events. Multiple risk factors for atherosclerosis are present in ESRD and may contribute to the increased risk of cardiovascular mortality in this population. In contrast to patients with normal renal function, the benefits of modifying lipid levels on cardiovascular outcomes in patients…
